Breakthroughs await! 🤗
Join Franz Weidinger and the other brilliant minds from across disciplines meeting at ESC Cardio-Oncology 2026 (19–20 June, Vienna, Austria).
It’s where you’ll learn and connect – and contribute to the solutions changing the future of cardio-oncology.
See you in Vienna at #ESCardioOnco26! https://t.co/DSUqGM0nSV
#cardioonc #cardioonco #oncology #radiology @ESCardioOnco
Delighted to join the 3rd edition of the COOL Podcast with Prof Ameri, discussing a common and clinically relevant challenge in daily practice. Join us at ESC Cardio-Oncology conference in Vienna for this topic and much more! #ESCardioOnco26
Education, collaboration & implementation are key in #CardioOncology
📚#ESCardioOnco Certification Programme & Exam:
🔗 https://t.co/KBHjJokZFa
Join the growing global #cardiooncology community in Vienna this June:
🔗 https://t.co/P0o8QV30NH
@escardio
#CardioOncology is getting increasingly complex
What should the next guideline cycle deliver?
📍Risk prediction tools
📍Personalized CV prevention & monitoring
📍CV endpoints in oncology trials
📍Survivorship pathways
📍Access beyond expert centres
📍Measurable patient impact
🎙️🚨New Podcast Alert!
How can cancer therapy impact blood pressure and vascular health?🩺❤️🩹
In our latest episode, Prof. Pietro Ameri 🇮🇹 and @LlamedoClara🇬🇧dive into “Hypertension and Vascular Toxicity in Cancer Therapy” #CardioOncology@ESC_Lavinia@TeresaLpezFdez1
Fantastic joint session FAC-ESC at the XLIII Congreso Nacional de Cardiología!
A great multidisciplinary discussion highlighting how #CardioOncology is evolving across prevention, monitoring, survivorship & HF care, a 🧵👇
@escardio@fac_cardio
The second episode of the podcast is now live - covering a highly relevant topic, especially given how often we see patients on HER2-targeted therapies!
@Massimi78530343@JLiu_MSKCardOnc
Why is #ESCardioOnco26 in Vienna so special?🫀
Professor Jutta Bergler-Klein @BerglerKlein, local host of the congress, highlights the fantastic science & multidisciplinary sessions.
⏳ Late fee ends 19/5/26!
Register now: https://t.co/P0o8QV30NH
#CardioOncology@escardio
🎧 How should we monitor the heart during HER2+ breast cancer therapy?
In this ESC CardioOncology #CardioTalk, Dr @Massimi78530343 & Dr @JLiu_MSKCardOnc discuss about HER2 cardiotoxicity, risk stratification, & monitoring to prevent #CTRCD
🎧: https://t.co/fFm35VsKQW
#ESCardioOnco26 doesn’t follow innovation – it anticipates it ⏩
Next month, cardiologists, oncologists, haematologists, radiotherapists and allied professionals from around the world will come together to shape what’s next in cardio-oncology. Discover a programme offering a 360° view of the field and register by 19 May to save 👉 https://t.co/DSUqGM0nSV
@TeresaLpezFdez1@slumberbell@DrRaulCordoba@BerglerKlein@FarmakisD@CiroSantoro17@ESCardioOnco #ESCCardioOnco
🌍 The ESC Council of Cardio-Oncology #CardioOnc at #HFA2026 in beautiful Barcelona🇪🇸 New projects, new research and new initiatives shaping the future 🚀
📍Want to know more? Join the Council and take part in the Vienna Congress in June 2026🇦🇹
Ahead of World Cancer Day (4 Feb) 🗓️ we’re spotlighting our Top 10 #CardioOnc articles📚—showcasing the field’s momentum, collaboration🤝🫀and the power of multidisciplinary care. Stay tuned! 🚀 https://t.co/WWtctdgjjD #ESCardioOnco26
🫀Can a patient with #HeartFailure still receive #anthracycline therapy?
Excellent & highly practical overview by @TeresaLpezFdez1@ESCardioOnco at #HeartFailure26:
��The heart-cancer connection goes far beyond CTR-CVT, HF & cancer share: common risk factors & pathways.
📍Before saying “yes” or “no” to #anthracyclines, ask 4 key questions:
- What is the HF phenotype?
- What is the cancer priority/prognosis?
- Are effective non-anthracycline alternatives available?
- Can we reduce & closely monitor CV risk?
📍Anthracyclines are not always absolutely contraindicated in HF.
Some patients may still proceed with:
- optimized HF therapy
- intensive surveillance
- cardioprotection strategies
- modified regimens
📍Management must be multidisciplinary.
The goal is balancing cancer outcomes & cardiovascular outcomes ⚖️
📍Sometimes the answer is:
✅ yes
⚠️ yes, with modification & close monitoring
❌ or no/alternative strategy
📍A really important reminder that modern cardio-oncology is no longer about simply stopping cancer therapy, but individualizing risk while preserving both cardiac & oncologic outcomes
#CardioOncology @escardio
🎙️The 1st episode of ESC CardioTalk: Cardio-Oncology is now LIVE🫀🩺
‘Which Patients Should Receive Pre-Treatment Cardiac Screening Before Chemotherapy or Immunotherapy?’
Discover expert insights and stay updated with the latest discussions🌍
👉Listen now https://t.co/YvILtCLtBf
Why join #ESCardioOnco26 in Vienna?
A true 360° view of #cardiooncology, cutting-edge science + real-world care.
- Practical, case-based sessions
- Tracks for all levels
- Focus on prevention & survivorship
⏳ Early reg ends 22 April
Register now: https://t.co/P0o8QV30NH
Excellent #EAPCI & #ESCCardioOnco joint session on #PCI in patients w/ cancer & ACS #EAPCI26
Clinical decisions must balance ischemic risk, bleeding risk & cancer prognosis.
Want to learn more?
Join #ESCardioOnco26 in Vienna,
19-20 June 26: https://t.co/P0o8QV30NH
@escardio
🌍Cardio-Oncology at the Heart of Cancer Care
The ESC CRT on #CardioOncology just concluded—with academia, regulators, industry & patients to shape a roadmap for CV safety,monitoring& survivorship.
Next stop➡️Vienna🇦🇹at #ESCardioOnco2026 to keep the momentum going. Don’t miss it!
More time to make an impact in #cardiooncology
📣 Abstract deadline extended for #ESCardioOnco26!
Abstracts: 3 Feb 26
Clinical cases: 5 Feb 26
Join the global cardio-oncology community in Vienna, 19-20 June: https://t.co/B41EGhERSV
#ESCCardioOnco@TeresaLpezFdez1